相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers
Bowen Sun et al.
ONCOGENE (2020)
ABC-transporter upregulation mediates resistance to the CDK7 inhibitors THZ1 and ICEC0942
Georgina P. Sava et al.
ONCOGENE (2020)
CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer
Hua Zhang et al.
CANCER CELL (2020)
CDK7 regulates organ size and tumor growth by safeguarding the Hippo pathway effector Yki/Yap/Taz in the nucleus
Yong Suk Cho et al.
GENES & DEVELOPMENT (2020)
Aberrant Super-Enhancer Landscape in Human Hepatocellular Carcinoma
Felice Ho-Ching Tsang et al.
HEPATOLOGY (2019)
THZ1 reveals CDK7-dependent transcriptional addictions in pancreatic cancer
Ping Lu et al.
ONCOGENE (2019)
Targeting Super-Enhancer-Driven Oncogenic Transcription by CDK7 Inhibition in Anaplastic Thyroid Carcinoma
Xinyi Cao et al.
THYROID (2019)
CDK7 inhibitor suppresses tumor progression through blocking the cell cycle at the G2/M phase and inhibiting transcriptional activity in cervical cancer
Shanshan Zhong et al.
ONCOTARGETS AND THERAPY (2019)
Discovery and Characterization of SY-1365, a Selective, Covalent Inhibitor of CDK7
Shanhu Hu et al.
CANCER RESEARCH (2019)
The Covalent CDK7 Inhibitor THZ1 Potently Induces Apoptosis in Multiple Myeloma Cells In Vitro and In Vivo
Yu Zhang et al.
CLINICAL CANCER RESEARCH (2019)
Efficacy of the novel CDK7 inhibitor QS1189 in mantle cell lymphoma
Yun Jung Choi et al.
SCIENTIFIC REPORTS (2019)
CDK7 inhibitor THZ1 inhibits MCL1 synthesis and drives cholangiocarcinoma apoptosis in combination with BCL2/BCL-XL inhibitor ABT-263
Tianlu Huang et al.
CELL DEATH & DISEASE (2019)
CDK7 Inhibition Suppresses Castration-Resistant Prostate Cancer through MED1 Inactivation
Reyaz Ur Rasool et al.
CANCER DISCOVERY (2019)
A high-throughput screen identifies that CDK7 activates glucose consumption in lung cancer cells
Chiara Ghezzi et al.
NATURE COMMUNICATIONS (2019)
Small-molecule targeting of brachyury transcription factor addiction in chordoma
Tanaz Sharifnia et al.
NATURE MEDICINE (2019)
Overexpression of CDK7 is associated with unfavourable prognosis in oral squamous cell carcinoma
Lei Jiang et al.
PATHOLOGY (2019)
Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy
Ali Alqahtani et al.
FUTURE SCIENCE OA (2019)
SY-5609, an orally available selective CDK7 inhibitor demonstrates broad anti-tumor activity in vivo
Shanhu Hu et al.
CANCER RESEARCH (2019)
Development of a Selective CDK7 Covalent Inhibitor Reveals Predominant Cell-Cycle Phenotype
Calla M. Olson et al.
CELL CHEMICAL BIOLOGY (2019)
Preclinical evaluation of PK, PD, and antitumor activity of the oral, non-covalent, potent and highly selective CDK7 inhibitor, SY-5609, provides rationale for clinical development in multiple solid tumor indications
Liv H. Johannessen et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Are all cyclin-dependent kinases 4/6 inhibitors created equal?
Antonio Marra et al.
NPJ BREAST CANCER (2019)
CDK9: a signaling hub for transcriptional control
Curtis W. Bacon et al.
TRANSCRIPTION-AUSTIN (2019)
Therapeutic targeting of transcriptional cyclin-dependent kinases
Matthew D. Galbraith et al.
TRANSCRIPTION-AUSTIN (2019)
Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations
Rinath Jeselsohn et al.
CANCER CELL (2018)
High MITF Expression Is Associated with Super-Enhancers and Suppressed by CDK7 Inhibition in Melanoma
Philip Eliades et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2018)
ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment
Hetal Patel et al.
MOLECULAR CANCER THERAPEUTICS (2018)
The essential and multifunctional TFIIH complex
Jenna K. Rimel et al.
PROTEIN SCIENCE (2018)
Inhibition of cyclin-dependent kinase 7 suppresses human hepatocellular carcinoma by inducing apoptosis
Liqiang Zhong et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2018)
Selective gene dependencies in MYCN-amplified neuroblastoma include the core transcriptional regulatory circuitry
Adam D. Durbin et al.
NATURE GENETICS (2018)
CDK7 inhibition is a novel therapeutic strategy against GBM both in vitro and in vivo
Wei Meng et al.
CANCER MANAGEMENT AND RESEARCH (2018)
Revisiting the role of ABC transporters in multidrug-resistant cancer
Robert W. Robey et al.
NATURE REVIEWS CANCER (2018)
Overcoming Resistance to the THZ Series of Covalent Transcriptional CDK Inhibitors
Yang Gao et al.
CELL CHEMICAL BIOLOGY (2018)
Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer
A. Harrod et al.
ONCOGENE (2017)
Preclinical Efficacy and Molecular Mechanism of Targeting CDK7-Dependent Transcriptional Addiction in Ovarian Cancer
Zhenfeng Zhang et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Inhibitors of cyclin-dependent kinases as cancer therapeutics
Steven R. Whittaker et al.
PHARMACOLOGY & THERAPEUTICS (2017)
THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors
Florencia Cayrol et al.
NATURE COMMUNICATIONS (2017)
Human TFIIH Kinase CDK7 Regulates Transcription-Associated Chromatin Modifications
Christopher C. Ebmeier et al.
CELL REPORTS (2017)
Activation of the p53 Transcriptional Program Sensitizes Cancer Cells to Cdk7 Inhibitors
Sampada Kalan et al.
CELL REPORTS (2017)
Cyclin-dependent kinase 7 is a therapeutic target in high-grade glioma
S. A. Greenall et al.
ONCOGENESIS (2017)
Enhancer profiling identifies critical cancer genes and characterizes cell identity in adult T-cell leukemia
Regina Wan Ju Wong et al.
BLOOD (2017)
Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer
Bo Li et al.
CANCER RESEARCH (2017)
A Review of Fulvestrant in Breast Cancer
Mark R. Nathan et al.
ONCOLOGY AND THERAPY (2017)
Transcriptional Dependencies in Diffuse Intrinsic Pontine Glioma
Surya Nagaraja et al.
CANCER CELL (2017)
Resistance to palbociclib depends on multiple targetable mechanisms highlighting the potential of drug holidays and drug switching to improve therapeutic outcome
L-A Martin et al.
CANCER RESEARCH (2017)
Inhibitor Selectivity for Cyclin-Dependent Kinase7: AStructural, Thermodynamic, and Modelling Study
Pascale Hazel et al.
CHEMMEDCHEM (2017)
Transcriptional Addiction in Cancer
James E. Bradner et al.
CELL (2017)
Expression of CDK7, Cyclin H, and MAT1 Is Elevated in Breast Cancer and Is Prognostic in Estrogen Receptor-Positive Breast Cancer
Hetal Patel et al.
CLINICAL CANCER RESEARCH (2016)
Upregulation of CDK7 in gastric cancer cell promotes tumor cell proliferation and predicts poor prognosis
Qiuhong Wang et al.
EXPERIMENTAL AND MOLECULAR PATHOLOGY (2016)
Upregulation of Cyclin-dependent Kinase 7 and Matrix Metalloproteinase-14 Expression Contribute to Metastatic Properties of Gastric Cancer
Ghodratolah Naseh et al.
IUBMB LIFE (2016)
Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors
Tinghu Zhang et al.
NATURE CHEMICAL BIOLOGY (2016)
PKC iota promotes cellular proliferation by accelerated G1/S transition via interaction with CDK7 in esophageal squamous cell carcinoma
Sujie Ni et al.
TUMOR BIOLOGY (2016)
Selective CDK7 inhibition with BS-181 suppresses cell proliferation and induces cell cycle arrest and apoptosis in gastric cancer
Bo-Yong Wang et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2016)
Structural and Functional Analysis of the Cdk13/Cyclin K Complex
Ann Katrin Greifenberg et al.
CELL REPORTS (2016)
CDK7 and miR-210 Co-regulate Cell-Cycle Progression of Neural Progenitors in the Developing Neocortex
Aisha I. Abdullah et al.
STEM CELL REPORTS (2016)
A Novel CDK7 Inhibitor of the Pyrazolotriazine Class Exerts Broad-Spectrum Antiviral Activity at Nanomolar Concentrations
Corina Hutterer et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
CDK7-Dependent Transcriptional Addiction in Triple-Negative Breast Cancer
Yubao Wang et al.
CELL (2015)
Characterization of Human Cyclin-Dependent Kinase 12 (CDK12) and CDK13 Complexes in C-Terminal Domain Phosphorylation, Gene Transcription, and RNA Processing
Kaiwei Liang et al.
MOLECULAR AND CELLULAR BIOLOGY (2015)
Architecture of the Human and Yeast General Transcription and DNA Repair Factor TFIIH
Jie Luo et al.
MOLECULAR CELL (2015)
THZ1 Reveals Roles for Cdk7 in Co-transcriptional Capping and Pausing
Kyle A. Nilson et al.
MOLECULAR CELL (2015)
The history and future of targeting cyclin-dependent kinases in cancer therapy
Uzma Asghar et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor
Camilla L. Christensen et al.
CANCER CELL (2014)
CDK7 Inhibition Suppresses Super-Enhancer-Linked Oncogenic Transcription in MYCN-Driven Cancer
Edmond Chipumuro et al.
CELL (2014)
Cyclin-Dependent Kinase 7 Controls mRNA Synthesis by Affecting Stability of Preinitiation Complexes, Leading to Altered Gene Expression, Cell Cycle Progression, and Survival of Tumor Cells
Timothy W. R. Kelso et al.
MOLECULAR AND CELLULAR BIOLOGY (2014)
TFIIH Phosphorylation of the Pol II CTD Stimulates Mediator Dissociation from the Preinitiation Complex and Promoter Escape
Koon Ho Wong et al.
MOLECULAR CELL (2014)
Targeting transcription regulation in cancer with a covalent CDK7 inhibitor
Nicholas Kwiatkowski et al.
NATURE (2014)
Discovery and saturation analysis of cancer genes across 21 tumour types
Michael S. Lawrence et al.
NATURE (2014)
Kin28 regulates the transient association of Mediator with core promoters
Celia Jeronimo et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2014)
The structure and substrate specificity of human Cdk12/Cyclin K
Christian A. Boesken et al.
NATURE COMMUNICATIONS (2014)
Control of Transcriptional Elongation
Hojoong Kwak et al.
ANNUAL REVIEW OF GENETICS, VOL 47 (2013)
Development of a cyclin-dependent kinase inhibitor devoid of ABC transporterdependent drug resistance
M. Kaliszczak et al.
BRITISH JOURNAL OF CANCER (2013)
Super-Enhancers in the Control of Cell Identity and Disease
Denes Hnisz et al.
CELL (2013)
The CDK-activating kinase Cdk7 Taking yes for an answer
Miriam Merzel Schachter et al.
CELL CYCLE (2013)
A Cdk7-Cdk4 T-Loop Phosphorylation Cascade Promotes G1 Progression
Miriam Merzel Schachter et al.
MOLECULAR CELL (2013)
Mutational landscape and significance across 12 major cancer types
Cyriac Kandoth et al.
NATURE (2013)
ARCH domain of XPD, an anchoring platform for CAK that conditions TFIIH DNA repair and transcription activities
Wassim Abdulrahman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
CDK4 T172 Phosphorylation Is Central in a CDK7-Dependent Bidirectional CDK4/CDK2 Interplay Mediated by p21 Phosphorylation at the Restriction Point
Xavier Bisteau et al.
PLOS GENETICS (2013)
Regulation of Cdk7 activity through a phosphatidylinositol (3)-kinase/PKC-ι-mediated signaling cascade in glioblastoma
Shraddha R. Desai et al.
CARCINOGENESIS (2012)
Genetic inactivation of Cdk7 leads to cell cycle arrest and induces premature aging due to adult stem cell exhaustion
Miguel Ganuza et al.
EMBO JOURNAL (2012)
A Universal RNA Polymerase II CTD Cycle Is Orchestrated by Complex Interplays between Kinase, Phosphatase, and Isomerase Enzymes along Genes
Alain R. Bataille et al.
MOLECULAR CELL (2012)
Cyclin-dependent kinase control of the initiation-to-elongation switch of RNA polymerase II
Stephane Larochelle et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2012)
TFIIB dephosphorylation links transcription inhibition with the p53-dependent DNA damage response
Jayasha Shandilya et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
The phosphorylation of the androgen receptor by TFIIH directs the ubiquitin/proteasome process
Pierre Chymkowitch et al.
EMBO JOURNAL (2011)
A novel PKC-ι inhibitor abrogates cell proliferation and induces apoptosis in neuroblastoma
Prajit Pillai et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2011)
Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies
Christophe Le Tourneau et al.
EUROPEAN JOURNAL OF CANCER (2010)
CDK12 is a transcription elongation-associated CTD kinase, the metazoan ortholog of yeast Ctk1
Bartlomiej Bartkowiak et al.
GENES & DEVELOPMENT (2010)
Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma
Wei-Gang Tong et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
The landscape of somatic copy-number alteration across human cancers
Rameen Beroukhim et al.
NATURE (2010)
p53 Research: The Past Thirty Years and the Next Thirty Years
David Lane et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2010)
SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples
Andrew Conroy et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
The Development of a Selective Cyclin-Dependent Kinase Inhibitor That Shows Antitumor Activity
Simak Ali et al.
CANCER RESEARCH (2009)
TFIIH-Associated Cdk7 Kinase Functions in Phosphorylation of C-Terminal Domain Ser7 Residues, Promoter-Proximal Pausing, and Termination by RNA Polymerase II
Kira Glover-Cutter et al.
MOLECULAR AND CELLULAR BIOLOGY (2009)
TFIIH Kinase Places Bivalent Marks on the Carboxy-Terminal Domain of RNA Polymerase II
Md. Sohail Akhtar et al.
MOLECULAR CELL (2009)
Nucleotide excision repair driven by the dissociation of CAK from TFIIH
Frederic Coin et al.
MOLECULAR CELL (2008)
Distinct Activation Pathways Confer Cyclin-Binding Specificity on Cdk1 and Cdk2 in Human Cells
Karl A. Merrick et al.
MOLECULAR CELL (2008)
A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors
Elisabeth I. Heath et al.
INVESTIGATIONAL NEW DRUGS (2008)
RNA polymerase II pauses and associates with pre-mRNA processing factors at both ends of genes
Kira Glover-Cutter et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2008)
Serine-7 of the RNA polymerase IICTD is specifically required for snRNA gene expression
Sylvain Egloff et al.
SCIENCE (2007)
Confirmation of a BRAF mutation-associated gene expression signature in melanoma
Peter Johansson et al.
PIGMENT CELL RESEARCH (2007)
Requirements for Cdk7 in the assembly of Cdk1/cyclin B and activation of Cdk2 revealed by chemical genetics in human cells
Stephane Larochelle et al.
MOLECULAR CELL (2007)
A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days
C. Benson et al.
BRITISH JOURNAL OF CANCER (2007)
Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia
John C. Byrd et al.
BLOOD (2007)
Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death
R Chen et al.
BLOOD (2005)
Differential regulation of estrogen-inducible proteolysis and transcription by the estrogen receptor α N terminus
CC Valley et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Dysregulation of the peroxisome proliferator-activated receptor target genes by XPD mutations
E Compe et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Seliciclib (CYC202, R-roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1
DE MacCallum et al.
CANCER RESEARCH (2005)
Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: Results from cancer and leukemia group B study 19805
JC Byrd et al.
CLINICAL CANCER RESEARCH (2005)
N-(Cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase -: 2.: N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent
RN Misra et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma
S Burdette-Radoux et al.
INVESTIGATIONAL NEW DRUGS (2004)
The cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of cyclin D1, and activates the mitogen-activated protein kinase pathway
SR Whittaker et al.
CANCER RESEARCH (2004)
The crystal structure of human CDK7 and its protein recognition properties
G Lolli et al.
STRUCTURE (2004)
Selective regulation of vitamin D receptor-responsive genes by TFIIH
P Drané et al.
MOLECULAR CELL (2004)
Microarray expression profiling in melanoma reveals a BRAF mutation signature
S Pavey et al.
ONCOGENE (2004)
Phase II study of flavopiridol in patients with advanced colorectal cancer
M Aklilu et al.
ANNALS OF ONCOLOGY (2003)
Flavopiridol in untreated or relapsed mantle-cell lymphoma: Results of a phase II study of the National Cancer Institute of Canada clinical trials group
CT Kouroukis et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy
G Freyer et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine)
SJ McClue et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
The cyclin H/cdk7/Mat1 kinase activity is regulated by CK2 phosphorylation of cyclin H
E Schneider et al.
ONCOGENE (2002)
Phosphorylation of human estrogen receptor α at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera
DS Chen et al.
ONCOGENE (2002)
XPD mutations prevent TFIIH-dependent transactivation by nuclear receptors and phosphorylation of RARα
A Keriel et al.
CELL (2002)
Human glioma PKC-ι, and PKC-βII phosphorylate cyclin-dependent kinase activating kinase during the cell cycle
M Acevedo-Duncan et al.
CELL PROLIFERATION (2002)
T-loop phosphorylation stabilizes the CDK7-cyclin H-MAT1 complex in vivo and regulates its CTD kinase activity
S Larochelle et al.
EMBO JOURNAL (2001)
Inability to enter S phase and defective RNA polymerase IICTD phosphorylation in mice lacking Mat1
DJ Rossi et al.
EMBO JOURNAL (2001)
Reciprocal activation by cyclin-dependent kinases 2 and 7 is directed by substrate specificity determinants outside the T loop
S Garrett et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
TFIIH is negatively regulated by cdk8-containing mediator complexes
S Akoulitchev et al.
NATURE (2000)
TFIIH interacts with the retinoic acid receptor γ and phosphorylates its AF-1-activating domain through cdk7
J Bastien et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
From androgen receptor to the general transcription factor TFIIH -: Identification of cdk activating kinase (CAK) as an androgen receptor NH2-terminal associated coactivator
DK Lee et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
分享论文
